The Conversation (0)
The US Food and Drug Administration has given final approval to Antares Pharma (NASDAQ:ATRS) for a new treatment for some types of arthritis and psoriasis.
The US Food and Drug Administration has given final approval to Antares Pharma (NASDAQ:ATRS) for a new treatment for some types of arthritis and psoriasis.
As quoted in the press release:
OTREXUP™ is the first FDA approved subcutaneous (SC) methotrexate (MTX) for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP™ is indicated for adults with severe active rheumatoid arthritis (RA) who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs), or children with active polyarticular juvenile idiopathic arthritis (pJIA). The FDA also approved adult use of OTREXUP™ for symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy.
Click here for the full press release by Antares Pharma (NASDAQ:ATRS)